Triple-Negative Breast Cancer
Drs Juneja, Graff, and Lustberg explore the most pressing topics in breast cancer, such as ADCs and post-CDK4/6 sequencing.
ADCs, ctDNA, and endocrine therapy advances headlined ASCO 2025 breast cancer updates across HER2+, HR+, and TNBC.
Triplet therapy showed promising efficacy in advanced TNBC in the ATRACTIB trial, with a 63% response rate.
Dr. Gradishar reviews PARP data, new combos, and tools to better select breast cancer patients for targeted treatment.
Dr. Mark Robson discusses PARP inhibitors in TNBC, including mechanisms, combos, biomarkers, and treatment sequencing.
Dr. Kelly McCann discusses evolving treatment sequencing strategies in metastatic triple-negative breast cancer.
Top research highlights from ESMO Breast Cancer 2025 showcase advances in treatment and care for patients with breast cancer.
Dr. David Waterhouse discusses geographic barriers to TNBC trials for Black women and the case for decentralized research.
TVEC plus chemo shows promise in early TNBC, boosting immune response and survival with favorable safety profile.
Emi-Le ADC shows promising activity in B7-H4–positive TNBC and endometrial cancer with a novel auristatin payload.
New ASCENT-04 data could shift first-line care in PD-L1+ TNBC. Dr. Rebecca Shatsky shares real-world insights from ASCO 2025.
Sacituzumab + pembrolizumab improved PFS vs chemo in PD-L1+ TNBC in ASCENT-04, with no new safety signals.
Sacituzumab + pembrolizumab improves PFS vs chemo in PD-L1+ TNBC, per ASCENT-04/KEYNOTE-D19 phase 3 trial at ASCO 2025.
Stephanie Graff, MD, reviews top ASCO25 breast cancer trials, including ASCENT-04, DESTINY-Breast09, and SERENA-6.
High CIG signature or high sTILs linked to better survival in stage I TNBC; findings support further prognostic evaluation.
Sacituzumab tirumotecan showed a 71% ORR and manageable safety in first-line advanced TNBC, regardless of PD-L1 status.
Emiltatug ledadotin showed early clinical activity and was well tolerated in heavily pretreated patients with TNBC.
Darolutamide did not meet the clinical benefit endpoint in AR-positive TNBC, per findings from the phase II START trial.
New staging model links treatment response to survival, refining breast cancer prognosis after neoadjuvant chemotherapy.
A new AJCC model refines breast cancer staging after neoadjuvant chemo, filling a key gap in patient prognostication.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.